Salvage radiation therapy (RT) showed efficacy in local control of relapsed or refractory large B-cell lymphoma (LBCL) following CD19-targeted chimeric antigen receptor (CAR) T-cell therapy failure.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Helsinn announces publication of latest mechlorethamine gel research, highlighting its efficacy .
Helsinn Healthcare S.A.February 18, 2021 GMT
Helsinn announces publication of latest mechlorethamine gel research, highlighting its efficacy and safety
Lugano, Switzerland, February 18, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to note two recent journal publications on the use of mechlorethamine gel 0.016% as a topical treatment of early stage mycosis fungoides-type cutaneous T-cell lymphoma (“MF-CTCL”).
Mechlorethamine gel 0.016%, also known as chlormethine gel, is approved for use in multiple countries including the US and EU and is marketed under the trade names VALCHLOR® and LEDAGA®. The authorized use for each country varies based on the design of the registrational trial and the individual hea
Helsinn announces publication of latest mechlorethamine gel research, highlighting its efficacy and safety
Helsinn announces publication of latest mechlorethamine gel
research, highlighting its efficacy and safety
Lugano, Switzerland, February 18, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to note two recent journal publications on the use of mechlorethamine gel 0.016% as a topical treatment of early stage mycosis fungoides-type cutaneous T-cell lymphoma (“MF-CTCL”).
Mechlorethamine gel 0.016%, also known as chlormethine gel, is approved for use in multiple countries including the US and EU and is marketed under the trade names VALCHLOR
® and LEDAGA
Helsinn announces publication of latest mechlorethamine gel research, highlighting its efficacy and safetyLugano, Switzerland, February 18, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to note two recent journal publications on the u.
Helsinn announces publication of latest mechlorethamine gel research, highlighting its efficacy and safety Lugano, Switzerland, February 18, 2021 - Helsinn, a Swiss pharmaceutical group focused